<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166555</url>
  </required_header>
  <id_info>
    <org_study_id>B0151004</org_study_id>
    <secondary_id>EudraCT 2010-019770-32</secondary_id>
    <nct_id>NCT01166555</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers</brief_title>
  <official_title>Phase I Pharmacokinetics And Tolerability Of PF-04236921 Following Subcutaneous Administration To Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and pharmacokinetics of PF-04236921
      administered as a single subcutaneous dose in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tolerability and Pharmacokinetics of subcutaneously administered dose of PF-04236921 in
      healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of clinical findings on physical examination</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in vital signs (blood pressure, pulse rate, oral or tympanic temperature) measurements</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in 12-lead electrocardiogram (ECG) parameters: PRI, RR, QRS, QT, QTcF (Freidericia's correction) and HR (heart rate)</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PF-04236921 concentrations will be determined by a validated assay and noncompartmental PK parameters</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of clinical laboratory abnormalities including absolute neturophil count, hepatic transaminases and bilirubin levels, and lipid profiles</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and level of ADA development</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04236921</intervention_name>
    <description>single subcutaneous dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males between 18-55 years, inclusive.

          -  Healthy females of non-childbearing potential between 18 and 55 years, inclusive.

        Exclusion Criteria:

          -  Evidence or history of clinically significant disease.

          -  Females of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0151004&amp;StudyName=Pharmacokinetics%20And%20Tolerability%20Of%20Subcutaneous%20Administration%20Of%20PF%2004236921%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <last_update_submitted>November 19, 2010</last_update_submitted>
  <last_update_submitted_qc>November 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Safety and tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>PF-04236921</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

